NASDAQ: SRZN - Surrozen, Inc.

Rentabilidad a seis meses: +36.01%
Rendimiento de dividendos: 0.00%
Sector: Healthcare

Calendario de promoción Surrozen, Inc.

Horario avanzado gráfico sencillo
Financial Markets by TradingView

Acerca de la empresa Surrozen, Inc.

Surrozen, Inc., a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair and regeneration. The company is developing antibody-based therapeutics with application across various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system.

más detalles
Its products in pipeline include SZN-043, a hepatocyte-specific R-spondin mimetic bispecific fusion protein, which is in Phase 1b clinical trial for the treatment of severe liver diseases, including alcoholic hepatitis and asialoglycoprotein receptor 1; and SZN-1326, a bi-specific antibody, which is in Phase 1b clinical trial for the treatment of moderate to severe inflammatory bowel disease, Frizzled, and LRP receptors. The company also develops SZN-413, a Fzd4 targeted bi-specific antibody, which is in preclinical stage for the treatment of retinal vascular associated diseases. Surrozen, Inc. has collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies. Surrozen, Inc. was founded in 2015 and is based in South San Francisco, California.
Añadir a la lista de comparación
Añadir a la lista de vigilancia
Añadir al portafolio
Añadir aviso de precio

IPO date 2021-01-11
ISIN US86889P1093
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.surrozen.com
Цена ао 13.65
Cambio de precio por día: -5.95% (14.78)
Cambio de precio por semana.: +31.57% (10.565)
Cambio de precio por mes: +36.01% (10.22)
Cambio de precio en 3 meses.: +35.61% (10.2499)
Cambio de precio en seis meses: +36.01% (10.22)
Cambio de precio por año: +47.87% (9.4)
Cambio de precio en 3 años.: +107.15% (6.71)
Cambio de precio en 5 años.: 0% (13.9)
Cambio de precio en 10 años.: 0% (13.9)
Cambio de precio desde principios de año.: +36.68% (10.17)
Todos los parámetros

Subestimación

Nombre Significado Calificación
P/S 1.35 9
P/BV 0.4458 10
P/E 0 0
EV/EBITDA 0.3831 10
Total: 6.13

Eficiencia

Nombre Significado Calificación
ROA, % -93.41 0
ROE, % -113.46 0
Total: 0

Dividendos

Nombre Significado Calificación
Div yield, % 0 0
DSI 0 0
Total: 0

Deber

Nombre Significado Calificación
Debt/EBITDA -0.0822 10
Total: 9.8

Impulso de crecimiento

Nombre Significado Calificación
Rentabilidad Revenue, % 0 0
Rentabilidad Ebitda, % 80.4 9
Rentabilidad EPS, % 416.44 10
Total: 7.2
Más detalles

Instituciones Volumen Compartir, %
Column Group LLC 627651 19.62
Euclidean Capital LLC 87696 2.74
Blackrock Inc. 58494 1.83
ArrowMark Colorado Holdings LLC 55123 1.72
Board Of Trustees Of The Leland Stanford Junior University 52131 1.63
Trustees Of Columbia University In The City Of New York 47930 1.5
Morgan Stanley 35211 1.1
Vanguard Group Inc 32511 1.02
Alyeska Investment Group, L.P. 20376 0.64
Geode Capital Management, LLC 11473 0.36

ETF Compartir, % Rentabilidad del año, % Dividendos, %
iShares Micro-Cap ETF 0.00519 17.09 1.54048



Supervisor Título profesional Pago año de nacimiento
Mr. Craig C. Parker M.B.A. CEO, President & Director 825.32k 1962 (63 año)
Mr. Charles Williams CFO, COO & Corporate Secretary 611.03k 1980 (45 años)
Dr. K. Christopher Garcia Ph.D. Co-Founder & Member of Scientific Advisory Board N/A
Dr. Roeland Nusse Ph.D. Co-Founder & Member of Scientific Advisory Board N/A 1950 (75 años)
Dr. Calvin Kuo M.D., Ph.D. Co-Founder & Member of Scientific Advisor N/A
Dr. Li Yang Ph.D. Executive Vice President of Research 535.46k 1969 (56 años)
Esther Jhun Controller N/A

DIRECCIÓN: United States, South San Francisco. CA, 171 Oyster Point Boulevard - abrir en mapas de google, abrir mapas de Yandex
Sitio web: https://www.surrozen.com